Alerta

TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS USING NANO POLYMERS OF HISTONE DEACETYLASE INHIBITORS

Resumen de: US2025302767A1

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and/or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and/or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and/or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and/or cancers; and methods for inhibiting the growth, proliferation, and/or metastasis of a tumor and/or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

IMMUNE ENGINEERING AMPLIFICATION

Resumen de: US2025302763A1

This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.

FORMULATIONS FOR ORAL DELIVERY OF POLYPEPTIDES, ANTIBODIES AND PROTEINS AND USES THEREOF

Resumen de: US2025302766A1

Provided is a nanoparticle comprising a composition comprising a polypeptide having a molecular weight greater than 50,000 g/mol (e.g. IgY antibodies), wherein the composition is encapsulated in a material that includes a biocompatible bioerodible polymer. Also provided is a method of preparing these nanoparticles, and use of the nanoparticles as a therapeutic to treat a disease condition.

FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER

Resumen de: US2025302751A1

Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano/microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.

TRIACETYL ANDROGRAPHOLIDE NANOCRYSTAL AND PREPARATION METHOD AND APPLICATION THEREOF

Resumen de: US2025302765A1

The triacetyl andrographolide nanocrystal is mainly composed of triacetyl andrographolide, a stabilizer and an excipient, and an average particle size of drug particles in a triacetyl andrographolide nanocrystal suspension obtained by redissolving the triacetyl andrographolide nanocrystal in water, is less than 500 nm, and a PDI is less than 0.2. The nanocrystal suspension is prepared from the triacetyl andrographolide and the stabilizer by a high-speed shear anti-solvent method in combination with a high-pressure homogenization method, then the excipient is added, and the nanocrystal is prepared through spray-drying.

SOLID LIPID NANOPARTICLES FOR ENCAPSULATION AND DELIVERY OF BIOACTIVE COMPOUNDS AND METHODS OF MAKING THE SAME

Resumen de: US2025302764A1

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

DEVICES, COMPOSITIONS AND RELATED METHODS FOR ACCELERATING AND ENHANCING BONE REPAIR

Resumen de: US2025302988A1

The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).

METHODS AND COMPOSITIONS FOR AGONISING TLR3

Resumen de: US2025302975A1

Provided herein are compositions and methods for inhibiting the growth of a mammalian cancer cell growth or stimulating the immune response of a mammal, by contacting the cell or administering to the mammal an effective amount of a viral nanoparticle comprising at least one TLR agonist and a chemotherapeutic agent.

Therapeutic Nanomaterials

Resumen de: US2025302971A1

Disclosed herein is a delivery vehicle based on DNA-inspired Janus based nanotubes (JBNTs) for anti-viral treatment. The nanoparticles (NPs) are based the JBNTs conjugated with targeting moieties such as small molecules, aptamers, and peptides.

Sulfur-Containing Lipids

Resumen de: US2025304547A1

Provided herein are novel sulfur-containing lipids having a structure of Formula A or a salt thereof. The compounds may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acids for use in the targeting of a non-liver organ, tissue or cell. Further provided are methods for making the compounds. (Formula A)

NOVEL LIPIDS BASED ON OLIGO-y-GLUTAMIC ACID DERIVATIVES AND LIPID NANOPARTICLES CONTAINING THE SAME, AND USES THEREOF

Resumen de: US2025302991A1

Provided are a novel lipid derivative compound including oligo-γ-glutamic acid, a lipid nanoparticle composition including the same, and the like. According to the present disclosure, the compound may form lipid nanoparticles by replacing PEGylated lipid, thereby preventing side effects such as anaphylaxis and exhibiting excellent in vivo stability, making it useful as a novel drug delivery system.

STING AGONIST-CONTAINING UREASE-POWERED NANOMOTOR-BASED BLADDER CANCER IMMUNOTHERAPY AGENT

Resumen de: US2025302989A1

A chitosan-heparin nanomotor and a method for producing same are disclosed. A STING agonist-encapsulated urease-based chitosan-heparin nanomotor delivers the STING agonist directly to bladder mucosal cells in the bladder, and thus can induce an immune response.

METHOD OF SYNTHESIS OF TARGETED LIPID NANOPARTICLE AND USES THEREOF

Resumen de: AU2024254671A1

The invention relates to a method for producing a lipid-based nanoparticle comprising an antigen binding domain and one or several nucleic acid molecule(s) using a mixing device, to a lipid-based nanoparticle comprising an antigen-binding domain and one or several nucleic acid molecule(s) obtainable trough such method and to uses thereof.

Targeted lipid nanoparticles

Resumen de: AU2025201939A1

The present invention relates to engineered targeted lipid nanoparticles (LNPs) comprising a nucleic acid, and compositions thereof, wherein the LNPs or compositions are capable of traversing the blood brain barrier (BBB) and delivering nucleic acid cargoes to a target tissue or cell in the central nervous system. In one aspect, the invention relates to the treatment of a neurological disease or disorder with a LNP or composition of the invention. The present invention relates to engineered targeted lipid nanoparticles (LNPs) comprising a nucleic acid, and compositions thereof, wherein the LNPs or compositions are capable of traversing the blood brain barrier (BBB) and delivering nucleic acid cargoes to a target tissue or cell in the central nervous system. In one aspect, the invention relates to the treatment of a neurological disease or disorder with a LNP or composition of the invention. ar a r h e p r e s e n t i n v e n t i o n r e l a t e s t o e n g i n e e r e d t a r g e t e d l i p i d n a n o p a r t i c l e s ( s ) c o m p r i s i n g a n u c l e i c a c i d , a n d c o m p o s i t i o n s t h e r e o f , w h e r e i n t h e s o r c o m p o s i t i o n s a r e c a p a b l e o f t r a v e r s i n g t h e b l o o d b r a i n b a r r i e r ( ) a n d d e l i v e r i n g n u c l e i c a c i d c a r g o e s t o a t a r g e t t i s s u e o r c e l l i n t h e c e n t r a l n e r v o u s s y s t e m n o n e a s p e c t , t h e i n v e n t i o n r e l a t e s t o t h e t r

METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES

Resumen de: AU2024250699A1

The present disclosure provides novel compounds, methods, and cell targeting mRNA vaccine formulations for targeted delivery, such as delivery to dendritic cells. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features specific for dendritic cells and a lipid tail for incorporated into the bilayer membrane of the formed lipid nanoparticle.

MUCOSAL- AND CELL-MEMBRANE PENETRATING PEPTIDES AND USES THEREOF

Resumen de: AU2024249750A1

Peptides which are capable of penetrating mucosal membranes or cell membranes are provided. In some aspects, functionalized peptide conjugates are provided. Compositions of peptide conjugates are disclosed, and methods of using such compositions are provided.

ENGINEERED NANOCOMPLEXES

Resumen de: AU2024229078A1

The present invention relates to nanocomplexes (NCs) comprising a polysaccharide nanoparticle (NP) and a hormone selected from insulin, glucagon, or glucagon-like protein-1, and uses thereof for reducing the blood glucose level, in particular, for the treatment of diabetes.

FERRITIN-BOROCAPTATE SODIUM NANOCAGES FOR THE TREATMENT OF TUMORS

Resumen de: WO2025202984A1

The present invention concerns h-ferritin complexes loaded with anti-tumoral drugs for the treatment of cancer through Boron Neutron Capture Therapy.

MRNA BASED ENZYME PRECURSOR AND PREPARATION METHOD THEREOF

Resumen de: WO2025203087A1

The present disclosure discloses a recombinant construct including a vector and a recombinant nucleic acid molecule (1). The vector including at least one promoter region (13). The recombinant nucleic acid molecule (1) is encoded at least by SEQ ID No. 1. The recombinant nucleic acid molecule (1) is disposed downstream of the at least one promoter region (13) to enable transcription of the recombinant nucleic acid molecule (1) by the promoter region (13) to a plurality of messenger ribonucleic acid (mRNA) molecules encoded by SEQ ID No. 9.

RNA FORMULATION

Resumen de: WO2025202360A1

The present invention relates to aqueous RNA compositions that are suitable for storage, comprising Tris, a saccharide, and phosphate anions. The present invention also relates to methods of producing such aqueous RNA compositions, as well as their use in therapy and prevention of infectious diseases.

LIPID NANOPARTICLE LOADED WITH ANTITUMORAL AGENT AND FUNCTIONNALIZED TO TARGET IMMOSUPPRESSIVE CELLS

Resumen de: WO2025202213A1

The present invention relates to lipid nanoparticle loaded with antitumoral agent and functionalized to target immunosuppressive cells. Inventors developpe valrubicin-loaded immunoliposomes (Val-ILs). A small amount of valrubicin incorporated into Val-ILs induces leukemia cell death in vivo, suggesting that Val-ILs could be used to treat acute leukemia cells. Inventors also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation. They also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen. The most efficient Val-ILs were found to be those loaded with CD11b,CD223, CD64, TIM1, CD200R3, CD204, CD49b, VEGFR2 and SIGLECF antibodies. This study provides the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death.

マルチアゴニストおよびその使用

Resumen de: US2025129135A1

The present application relates to the pharmaceutical and biological fields, particularly relates to a polypeptide compound of general formula (I) with triple agonist activity on glucagon like peptide-1 receptor (GLP-1 R), glucose-dependent insulinotropic polypeptide receptor (GIP R), and glucagon receptor (GCG R), and use thereof in the treatment of metabolic syndrome.

NOVEL LIPIDS BASED ON OLIGO-Y-GLUTAMIC ACID DERIVATIVES AND LIPID NANOPARTICLES CONTAINING THE SAME, AND USES THEREOF

Resumen de: EP4624516A1

Provided are a novel lipid derivative compound including oligo-γ-glutamic acid, a lipid nanoparticle composition including the same, and the like. According to the present disclosure, the compound may form lipid nanoparticles by replacing PEGylated lipid, thereby preventing side effects such as anaphylaxis and exhibiting excellent in vivo stability.

C6'-SUBSTITUTED LOCKED NUCLEIC ACID-MODIFIED CAP ANALOG AND USE THEREOF

Resumen de: EP4624462A2

The present disclosure provides a C6'-substituted locked nucleic acid-modified cap analog and a use thereof, wherein the cap analog improves the stability of mRNA and/or the translation efficiency of mRNA.

IONIZABLE LIPIDS AND LIPID NANOPARTICLES CONTAINING THEREOF

Nº publicación: EP4622956A1 01/10/2025

Solicitante:

CERTEST BIOTEC S L [ES]
Certest Biotec, S.L

Resumen de: CN120225501A

The present invention provides an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer of any of them; a lipid nanoparticle comprising the ionizable lipid (in particular as an encapsulant), optionally comprising a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid nanoparticles. The present invention also provides a lipid nanoparticle for a drug or a pharmaceutical composition comprising the same, and a use of the lipid nanoparticle as an encapsulant. # imgabs0 #